Role of the orphan nuclear receptor ROR alpha in the control of the metastatic behavior of androgen-independent prostate cancer cells.

EZH2 in Bladder Cancer, a Promising Therapeutic Target. Int J Mol Sci (2015) 0.85

The molecular genetics of autism spectrum disorders: genomic mechanisms, neuroimmunopathology, and clinical implications. Autism Res Treat (2011) 0.75

Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data. PLoS One (2011) 0.75

miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res (2009) 2.52

The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype. Cancer Res (2005) 1.19

The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans. Front Neuroendocrinol (2003) 1.00

Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the alphavbeta3 integrin and PI3-K/Akt signaling. Int J Oncol (2006) 0.97

Free and bound plasma leptin in normal weight and obese men and women: relationship with body composition, resting energy expenditure, insulin-sensitivity, lipid profile and macronutrient preference. Clin Endocrinol (Oxf) (2005) 0.96

Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells. Endocrinology (2005) 0.95

Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models. Endocrinology (2011) 0.92

Clusterin isoforms differentially affect growth and motility of prostate cells: possible implications in prostate tumorigenesis. Cancer Res (2007) 0.88

GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocr Rev (2012) 0.87

Gonadotropin-releasing hormone agonists suppress melanoma cell motility and invasiveness through the inhibition of alpha3 integrin and MMP-2 expression and activity. Int J Oncol (2008) 0.86

Modulatory actions of neuropeptide Y on prostate cancer growth: role of MAP kinase/ERK 1/2 activation. Adv Exp Med Biol (2007) 0.86

PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer. Endocr Relat Cancer (2013) 0.85

Schwann-like adult stem cells derived from bone marrow and adipose tissue express γ-aminobutyric acid type B receptors. J Neurosci Res (2011) 0.84

Activation of the orphan nuclear receptor RORalpha counteracts the proliferative effect of fatty acids on prostate cancer cells: crucial role of 5-lipoxygenase. Int J Cancer (2004) 0.83

Long-term presence of androgens and anti-androgens modulate EGF-receptor expression and MAP-kinase phosphorylation in androgen receptor-prostate positive cancer cells. Int J Oncol (2004) 0.82

Molecular mechanisms of the antimetastatic activity of nuclear clusterin in prostate cancer cells. Int J Oncol (2011) 0.82

Locally expressed LHRH receptors mediate the oncostatic and antimetastatic activity of LHRH agonists on melanoma cells. J Clin Endocrinol Metab (2002) 0.81

Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib. Prostate (2011) 0.81

Type I gonadotropin-releasing hormone receptor mediates the antiproliferative effects of GnRH-II on prostate cancer cells. J Clin Endocrinol Metab (2009) 0.81

Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate (2010) 0.80

The synthesis of glycoprotein Po and peripheral myelin protein 22 in sciatic nerve of male rats is modulated by testosterone metabolites. Brain Res Mol Brain Res (2004) 0.80

Altered peripheral myelination in mice lacking GABAB receptors. Mol Cell Neurosci (2007) 0.80

Role of neuropeptide Y and its receptors in the progression of endocrine-related cancer. Peptides (2007) 0.79

Leukemia inhibitory factor induces the chemomigration of immortalized gonadotropin-releasing hormone neurons through the independent activation of the Janus kinase/signal transducer and activator of transcription 3, mitogen-activated protein kinase/extracellularly regulated kinase 1/2, and phosphatidylinositol 3-kinase/Akt signaling pathways. Mol Endocrinol (2007) 0.79

Characterization of prostate cancer DU145 cells expressing the recombinant androgen receptor. Oncol Res (2003) 0.78

Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I. Int J Oncol (2007) 0.77

Dual targeting of tumor and endothelial cells by gonadotropin-releasing hormone agonists to reduce melanoma angiogenesis. Endocrinology (2010) 0.77

SRC-1 is involved in the control of the gene expression of myelin protein Po. J Mol Neurosci (2004) 0.76

Cholinergic regulation of neuropeptide Y synthesis and release in human neuroblastoma cells. Peptides (2007) 0.76

Evaluation of a stable gonadotropin-releasing hormone analog in mice for the treatment of endocrine disorders and prostate cancer. J Pharmacol Exp Ther (2010) 0.76

Novel insights into GnRH receptor activity: role in the control of human glioblastoma cell proliferation. Oncol Rep (2009) 0.76

Regulation of prostate cancer cell proliferation by somatostatin receptor activation. Mol Cell Endocrinol (2009) 0.75

In memoriam. Professor Antonio Liuzzi (1939-2013). J Endocrinol Invest (2013) 0.75

Aldosterone receptor antagonists: biology and novel therapeutic applications. Curr Hypertens Rep (2005) 0.75

Total, free and bound leptin and thyroid function in elderly women with different body weights. Clin Endocrinol (Oxf) (2007) 0.75